- Eli Lilly plans to launch its new weight-loss pill in Europe and the UK in late 2026 or early 2027, after recent approvals in the U.S. and UAE.
- The company will lean on telehealth, e‑commerce and direct-to-patient channels so most European sales would be paid out‑of‑pocket rather than through public health systems.
- Lilly will still seek public reimbursement where possible, but U.S. "most‑favoured‑nation" pricing rules complicate negotiations with European governments.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.